Opna

Opna’s broad portfolio targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-X mental retardation protein (FMRP), with the rationale that inhibition of FMRP in cancer cells would enable the body to launch an immune response against tumors that are otherwise resistant to immune attack